Oorsprong van het eerstegraads netwerk van Sean R. Smith
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
ImmunOs Therapeutics AG
ImmunOs Therapeutics AG BiotechnologyHealth Technology ImmunOs Therapeutics AG is a company based in Schlieren, Switzerland that pioneers HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Swiss company has identified specific HLA molecules that activate the immune system and is utilizing these molecules as the backbone of novel therapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs' lead program is a multi-functional fusion protein that blocks specific LILRB and KIR receptors and activates anti-tumor responses. The company is also using HLA molecules to develop novel therapies to treat inflammatory diseases. ImmunOs is supported by leading international investors, including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Biomed Partners, Schroder Adveq, Mission BioCapital, GL Capital, Peak6, Fiscus, and Redalpine. The company was founded by Osiris Marroquin Belaunzaran and Christoph Renner, and the CEO is Sean R. Smith.
11
| Holding Company | Biotechnology | 11 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Sean R. Smith via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
AMGEN INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal | |
Cephalon, Inc.
Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
PEPSICO, INC. | Food: Specialty/Candy | Director/Board Member | |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Cylene Pharmaceuticals, Inc.
Cylene Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cylene Pharmaceuticals, Inc. discovers, develops and commercializes small molecule drugs. It develops molecule drugs to treat life-threatening diseases, with a particular emphasis in oncology. The firm drug discovery platform, STAND has delivered a diverse portfolio of drug candidates that target the multiple pathways critical for the support, maintenance of cancer cells and that address unmet medical needs with substantial markets. The company was founded in 1997 by Thomas James Farrell and Daniel Douglas Von Hoff and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Director/Board Member | |
Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Novartis Corp.
Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Viridos, Inc.
Viridos, Inc. Miscellaneous Commercial ServicesCommercial Services Viridos, Inc. develops and commercializes genomic-driven solutions and products. The firm's offerings are designed for application in solutions such as human health, food, water production, and environment. The company was founded by J. Craig Venter, Hamilton O. Smith, David C. Kiernan and Juan Enriquez-Cabot in February 2005 and is headquartered in La Jolla, CA. | Miscellaneous Commercial Services | Director/Board Member | |
AILERON THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
FORMA Therapeutics, Inc.
FORMA Therapeutics, Inc. BiotechnologyHealth Technology FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA. | Biotechnology | Director/Board Member | |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | Pharmaceuticals: Major | Director/Board Member | |
Brown University | College/University | Undergraduate Degree | |
NOVARTIS AG | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal | |
University of Virginia | College/University | Graduate Degree | |
MIRATI THERAPEUTICS | Biotechnology | Chief Tech/Sci/R&D Officer | |
Syracuse University | College/University | Undergraduate Degree | |
St. Louis University | College/University | Doctorate Degree | |
Santa Clara University | College/University | Undergraduate Degree | |
ESBATech, a Novartis Co. GmbH
ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Miscellaneous Commercial Services | Director/Board Member | |
Pfizer Venture Investments LLC
Pfizer Venture Investments LLC Investment ManagersFinance Pfizer Ventures Investments LLC (Pfizer Ventures Investments) is a venture capital subsidiary of Pfizer Inc. founded in 2001. The firm is headquartered in New York. | Investment Managers | Private Equity Investor | |
Genedata AG
Genedata AG Packaged SoftwareTechnology Services Genedata AG transforms data into intelligence with a portfolio of advanced software solutions. Its products include biologics, screener, expressionist, profiler, analyst, phylosospher, selector, imagence and bioprocess. The firm offers data analysis, information technology, training, software, development and hosting services to pharmaceutical, agrochemical, Industrial biotechnology companies and non-profit research organizations. The company was founded by Othmar Pfannes in 1997 and is headquartered in Basel, Switzerland. | Packaged Software | Chairman | |
University of Regensburg | College/University | Doctorate Degree | |
SYMETIS SA | Biotechnology | Director/Board Member | |
Robert Wood Johnson Medical School | College/University | Doctorate Degree | |
Eilenberg & Krause LLP
Eilenberg & Krause LLP Miscellaneous Commercial ServicesCommercial Services Eilenberg & Krause LLP provides legal services. The private company is based in New York, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Novartis Bioventure Fund
Novartis Bioventure Fund Investment ManagersFinance Novartis Bioventure Fund focuses on companies operating in the field of life science technology. The geographical focus includes the US, Canada, UK and Switzerland. The fund invests in biotechnology, pharmaceuticals and medical device products. It invests in all stages of financing and also invests in mezzanine transactions. | Investment Managers | President | |
NC Life Sciences Organization
NC Life Sciences Organization Miscellaneous Commercial ServicesCommercial Services North Carolina Biosciences Organization is non-profit organization, which focuses on legislative monitoring and lobbying activities at the state and federal level. The company was founded in 1994 and is headquartered in Durham, NC. | Miscellaneous Commercial Services | Director/Board Member | |
DC Bio Corp.
DC Bio Corp. BiotechnologyHealth Technology DC Bio Corp. develops technology for application to cancer and diseases associated with chronic viral infections. The company is headquartered in Halifax, Canada. | Biotechnology | Director/Board Member | |
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Universidad Peruana Cayetano Heredia | College/University | Undergraduate Degree | |
The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin | |
Rutgers Business School | College/University | Masters Business Admin | |
ARMO BIOSCIENCES INC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
ADAPTIVE BIOTECHNOLOGIES CORPORATION | Biotechnology | Private Equity Investor | |
SYNTHORX, INC. | Biotechnology | Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer | |
Novadip Biosciences SA
Novadip Biosciences SA BiotechnologyHealth Technology Novadip Biosciences SA operates as a advanced biopharmaceutical company that develops cell-based therapies to treat patients with critical size bone defects and severe bone diseases. Its proprietary product, Creost, is a natural scaffold-free and tridimensional bone structure, which reconstructs large bone defects without the need of any biomaterial. The firm is a osteogenic living implant with a mineralization similar to a real bone. Its Creost is an autologous cell based-therapy product obtained from Adipose-derived Mesenchymal Stem Cells (AMSCs) which promotes (i) a perfect engraftment without any scaffold and (ii) a tissue remodeling with all native bone properties. Novadip Biosciences was founded by Jean-Fran?ois Pollet and Denis Dufrane in 2013 and is headquartered in Louvain-la-Neuve, Belgium. | Biotechnology | Chief Executive Officer | |
Imcheck Therapeutics SAS
Imcheck Therapeutics SAS Pharmaceuticals: MajorHealth Technology Imcheck Therapeutics SAS operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research. The company was founded by Olive Daniel in 2015 and is headquartered in Marseille, France. | Pharmaceuticals: Major | Director/Board Member | |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | Investment Managers | Private Equity Investor | |
Lumen Bioscience, Inc.
Lumen Bioscience, Inc. Pharmaceuticals: OtherHealth Technology Lumen Bioscience, Inc. operates as a clinical stage biotechnology company which engages in the manufacture of therapeutic biologics for oral delivery. It focuses on the development of the blue-green algae Spirulina as an industrial scale production platform. The company was founded by Brian Finrow and James Roberts in 2017 and is headquartered in Seattle, WA. | Pharmaceuticals: Other | Director/Board Member | |
AFFLUENT MEDICAL | Medical Specialties | Director/Board Member | |
Magnolia Neurosciences Corp.
Magnolia Neurosciences Corp. BiotechnologyHealth Technology Magnolia Neurosciences Corp. operates as a drug discovery and development company. The firm focuses on the creation of a novel class of neuroprotective medicines. The company was founded in 2018 and is headquartered in Seattle, WA. | Biotechnology | Director/Board Member | |
Mediar Therapeutics, Inc.
Mediar Therapeutics, Inc. BiotechnologyHealth Technology Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member Director/Board Member | |
Artidis AG
Artidis AG Medical SpecialtiesHealth Technology Artidis AG develops nano mechanical biomarkers for rapid cancer diagnostics. The private company is based in Basel, Switzerland. The Swiss company was founded by Marija Plodinec, Marko Loparic, Philipp Oertle, Tobias Appenzeller. Marija Plodinec has been the CEO since incorporation. | Medical Specialties | Director/Board Member | |
Versameb AG
Versameb AG Miscellaneous Commercial ServicesCommercial Services Versameb AG operates as an preclinical-stage biopharmaceutical company. The company was founded by Friedrich Metzger, Roger Meier and Urs Breitenstein in 2018 and is headquartered in Basel, Switzerland. | Miscellaneous Commercial Services | Chairman | |
Enlaza Therapeutics, Inc.
Enlaza Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Enlaza Therapeutics, Inc. is a company that develops novel classes of protein therapeutics using their proprietary war-lock™ platform. The company is based in La Jolla, CA. The company's platform utilizes synthetic biology technology for site-specific covalent coupling driven by drug binding. Enlaza Therapeutics is pioneering the field of covalent biologics and is building a pipeline of first-in-class covalent biologics. The CEO of the company is Sergio G. Duron. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member |
Statistieken
Internationaal
Verenigde Staten | 35 |
Zwitserland | 9 |
Frankrijk | 3 |
Spanje | 2 |
Duitsland | 2 |
Sectoraal
Health Technology | 29 |
Consumer Services | 11 |
Commercial Services | 7 |
Finance | 4 |
Consumer Non-Durables | 2 |
Operationeel
Director/Board Member | 81 |
Private Equity Investor | 14 |
Corporate Officer/Principal | 13 |
Chairman | 11 |
Doctorate Degree | 8 |
Sterkste connecties
Insiders | |
---|---|
Shelley Chu | 31 |
Daniel Vasella | 25 |
Reinhard Ambros | 20 |
Markus Hosang | 15 |
Michael Baran | 14 |
Joseph Leveque | 12 |
Marcos Milla | 10 |
Jeffrey D. Abbey | 9 |
Andreas Jurgeit | 8 |
Osiris Marroquin Belaunzaran | 1 |
Christoph Renner | 1 |
- Beurs
- Insiders
- Sean R. Smith
- Bedrijfsconnecties